GLP-1/GIP receptor agonists - clinical practice guide

18 June 2024

ANZCA, along with peak diabetes, obesity and gastroenterological bodies, has produced clinical practice recommendations for patients using GLP-1/GIP receptor agonists.

In response to recent case reports of retained gastric contents and pulmonary aspiration during sedation for endoscopic procedures or general anaesthesia in people with diabetes and/or obesity treated with GLP-1 receptors agonists (GLP-1RAs), a clinical practice recommendation regarding the periprocedural use of GLP-1RAs/GIP Receptor Agonists (GIPRAs) has been co-authored by representatives from ANZCA (through its Safety and Quality Committee), the Australian Diabetes Society, National Association of Clinical Obesity Service, and the Gastroenterological Society of Australia

To be reviewed in December as more evidence and feedback is gathered, Clinical Practice Recommendation On Periprocedural Use Of GLP-1/GIP Receptor Agonists represents a consensus based on review of currently available evidence and consensus expert opinion. Although the current level of evidence is weak to inform a guideline, this document was written to mitigate the risk of pulmonary aspiration with the periprocedural use of GLP-1RAs/GIPRAs which, although rare, is potentially fatal.

If you have any queries or would like to provide feedback about the guideline, please email [email protected].

Last updated 10:48 1.07.2024